On air · 1 of 3 networks
mAbxience
- mabxience.com
- ES
- 1,271 employees
mAbxience’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 32. Watch mAbxience with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 3 | Checked 29 Oct 2026 | See all 32 ads → | ||
| Meta | Not checked | — | |||
| Recently | 39 | Ads on the Google Ads Transparency Center | Checked 3 Oct 2026 | Collect them with the API → |
mAbxience has 3 live LinkedIn ads. We recorded 39 Google ads on 3 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 1 Oct 2026
EN: Today marks the beginning of a new chapter for mAbxience. What started with a clear ambition, making high-quality biologics accessible to more patients around the world, has grown into a global biopharmaceutical company powered by talented people, scientific excellence and an entrepreneurial spirit that continues to define who we are. The completion of Fresenius Group' acquisition of mAbxience builds on a successful partnership and creates new opportunities for innovation, growth and patient impact. While ownership changes, what makes mAbxience special does not: our people, our expertise, our commitment to quality and our dedication to customers, partners and patients. To everyone who has been part of this journey, thank you. The next chapter starts today. ES: Hoy comienza un nuevo capítulo para mAbxience. Lo que comenzó con una ambición clara, hacer que medicamentos biológicos de alta calidad sean accesibles para más pacientes en todo el mundo, se ha convertido en una compañía biofarmacéutica global impulsada por el talento de sus personas, la excelencia científica y un espíritu emprendedor que sigue definiendo quiénes somos. La culminación de la adquisición de mAbxience por parte de Fresenius Group se basa en una colaboración de éxito y abre nuevas oportunidades para la innovación, el crecimiento y un mayor impacto en los pacientes. Este nuevo paso fortalece nuestra capacidad para seguir desarrollando y proporcionando biosimilares de alta calidad a nivel global. Aunque nuestra estructura accionarial evoluciona, lo que hace especial a mAbxience permanece intacto: nuestras personas, nuestra experiencia, nuestro compromiso con la calidad y nuestra dedicación a clientes, socios y pacientes. A todos los que han formado parte de este recorrido, gracias. El próximo capítulo comienza hoy. #mAbxience #Fresenius #Biopharma #Biosimilars #Innovation #PatientsFirst
- LINKEDIN · IMAGESince 30 Sept 2026
📅Book a meeting with Iván Sánchez, our R&D Director at CPHI Milan 2026, October 6–8. Write to [email protected] and visit us at Stand 7B130. #CPHI2026 #Biopharma #CDMO #mAbxience #PharmaManufacturing #Networking
- LINKEDIN · IMAGESince 30 Sept 2026
📅Meet the mAbxience team at CPHI Milan 2026, October 6–8. Book a meeting at [email protected] and visit us at Stand 7B130. #CPHI2026 #Biopharma #CDMO #mAbxience #PharmaManufacturing #Networking
- LINKEDIN · IMAGESince 30 Sept 2026
📅Book a meeting with Ayman Ibrahim, our Chief Operations Officer at CPHI Milan 2026, October 6–8. Write to [email protected] and visit us at Stand 7B130. #CPHI2026 #Biopharma #CDMO #mAbxience #PharmaManufacturing #Networking
- LINKEDIN · CAROUSELSince 29 Sept 2026
📅Meet the mAbxience Opeations team at CPHI Milan 2026, October 6–8. Book a meeting at [email protected] and visit us at Stand 7B130. #CPHI2026 #Biopharma #CDMO #mAbxience #PharmaManufacturing #Networking
- LINKEDIN · CAROUSELSince 28 Sept 2026
📅Meet the mAbxience Regulatory and R&D team at CPHI Milan 2026, October 6–8. Book a meeting at [email protected] and visit us at Stand 7B130. #CPHI2026 #Biopharma #CDMO #mAbxience #PharmaManufacturing #Networking
6 of 32 adsSign up to see every mAbxience ad, filter by format and date, and get alerts on new ones.
See all 32 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.